Skip to main content

Table 2 Therapeutics data and evolution during ICU stay of patients with severe pneumococcal pneumonia*

From: Severe pneumococcal pneumonia: impact of new quinolones on prognosis

Characteristics Overall population n = 70 Group A n = 38 Group B n = 32 P
Cephalosporin in initial treatment 46 (65.7%) 20 (52.6%) 26 (81.3%) 0.01
Use of drotrecogin alpha 4 (5.7%) 0 4 (12.5%) 0.02
Intensive insulin therapy 30 (42.8%) 4 (10.5%) 26 (81.2%) <0.0001
Use of hydrocortisone 24 (34.3%) 6 (15.7%) 18 (56.3%) 0.0004
Haemodialysis 10 (14.3%) 3 (7.8%) 7 (21.8%) 0.09
Body temperature on D3 37.4 ± 1.3 37.8 ± 1.0 36.9 ± 1.3 0.0008
SOFA score on D3 7.5 ± 4.8 8.0 ± 5.1 7.1 ± 4.5 0.48
Improvement on D3 43 (61.4%) 20 (52.6%) 23 (71.8%) 0.09
Body temperature on D5 37.5 ± 0.9 37.7 ± 0.9 37.3 ± 0.9 0.22
SOFA score on D5 6.4 ± 4.8 7.5 ± 4.9 5.5 ± 4.5 0.13
Body temperature on D7 37.4 ± 1.0 37.7 ± 0.9 37.0 ± 1.0 0.04
SOFA score on D7 6.6 ± 5.0 7.7 ± 5.0 5.6 ± 4.8 0.17
Sepsis-related complications 31 (44.3%) 16 (42.1%) 15 (46.8%) 0.68
HA-LRT superinfections 17 (24.3%) 7 (18.4%) 10 (31.2%) 0.21
ICU-related complications 12 (17.1%) 8 (21.0%) 4 (12.5%) 0.34
Duration of MV (days) 11.3 ± 14.3 11.2 ± 15.6 11.5 ± 12.9 0.93
Duration of vasopressor use (days) 3.5 ± 4.8 3.6 ± 5.6 3.3 ± 3.9 0.80
LOS in ICU (days) 14.6 ± 16.3 14.5 ± 19.0 14.6 ± 12.6 0.97
Mortality on D-15 14 (20%) 12 (31.6%) 2 (6.3%) 0.02
Mortality in ICU 26 (37.1%) 17 (44.8%) 9 (28.1%) 0.15
  1. *Data are presented as No. (%) or mean ± SD
  2. MV: mechanical ventilation; SAPS: simplified acute physiology score; LOD score: logistic organ dysfunction score: SOFA: Sepsis-related Organ Failure Assessment score; PSI: Pneumonia Severity Index; HA-LRT superinfections: hospital-acquired lower respiratory tract superinfections; LOS = length of stay.